{
  "docId": "019de071-b6aa-745b-9366-85da01204b7f",
  "docSlug": "36e600bcc4f8cdbd41dc817cb6eec90e",
  "documentTitle": "Bausch Health Companies | Results Presentation Deck | 91 slides",
  "authorId": "bausch-health-companies",
  "authorName": "Bausch Health",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 17,
  "pageCount": 91,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 4,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-b6aa-745b-9366-85da01204b7f/17",
  "deckHref": "/decks/019de071-b6aa-745b-9366-85da01204b7f",
  "deckJsonHref": "/decks/019de071-b6aa-745b-9366-85da01204b7f.json",
  "deckAnchorHref": "/decks/019de071-b6aa-745b-9366-85da01204b7f#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.18,
        "w": 0.92,
        "x": 0.04,
        "y": 0.315
      },
      "kind": "list",
      "text": "XIPERE: First and only therapy in U.S. utilizing suprachoroidal space for macular edema; expect availability Q1 2022.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "14e8272d-1490-437d-969b-c888d31c1ce2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.92,
        "x": 0.04,
        "y": 0.125
      },
      "kind": "list",
      "text": "INFUSE: Launched into fastest growing contact lens category; U.S. market ~$1B growing to ~$3B by 2030; Additional SiHy Daily Launches.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31fe1119-9534-41bf-b3a9-10ee609ca688",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.92,
        "x": 0.04,
        "y": 0.515
      },
      "kind": "list",
      "text": "NOV03: Demonstrated efficacy/safety in Phase 3; all endpoints achieved; anticipate NDA filing 1H22.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "38ec2439-40c9-4074-ba7b-598d7d1fea72",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.715
      },
      "kind": "list",
      "text": "Lucentis Biosimilar: Licensed exclusive rights from STADA and Xbrane; Xbrane expected to file aBLA in 4Q21.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "57ae901e-db85-4f14-a577-93e3380833e1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.72,
        "x": 0.26,
        "y": 0.895
      },
      "kind": "source-note",
      "text": "Footnotes 1-8 detailing market data, clinical trial status, and regulatory filings.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ea80835-1a09-4e7d-a15f-00408336e1b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.58,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "Executing on Late-Stage Programs",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa9a9d4d-6ce4-476e-929d-88c2377ab070",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 16,
      "beatId": "3301686e-d32a-433b-8780-603c1ac68052",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The document presents growth initiatives and strategic alternatives",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 28,
      "from": 16,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "21cf5b4a-ca72-4285-ac92-38cb6528cb3d",
      "evidence": "The document highlights late-stage programs and recovery in progress",
      "position": 1,
      "objective": "Presenting growth initiatives",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}